Go to the list of all blogs
John Y White's Avatar
published in Blogs
Oct 05, 2026
3D Systems (DDD) vs. Flyte Aviation (VJET): Contrasting Paths in 3D Technology

3D Systems (DDD) vs. Flyte Aviation (VJET): Contrasting Paths in 3D Technology

Key Takeaways

  • DDD (3D Systems) is an established additive manufacturing company with a market capitalization near $600 million and improving, near-breakeven profitability.
  • VJET is the newly adopted ticker for Flyte Aviation, a micro-cap that recently pivoted from cardiac medical devices into private regional aviation and completed a reverse stock split.
  • The two companies differ sharply in scale, business model, financial stability, and risk profile, despite both operating around three-dimensional technology and hardware.
  • 3D Systems has shown broad-based momentum in healthcare and aerospace, while Flyte Aviation is in the early stages of a capital-intensive strategic transformation.
  • Relative performance diverges widely, with DDD posting strong year-to-date gains and VJET trading near its lows ahead of a corporate restructuring.

Introduction

Investors often look at companies that share a broad theme but sit at very different stages of development. That dynamic is clear with 3D Systems and Flyte Aviation. 3D Systems is a long-standing leader in 3D printing and additive manufacturing, while Flyte Aviation, which adopted the VJET ticker in early October 2026, is a micro-cap shifting from cardiac electrophysiology devices into technology-enabled private aviation. This comparison matters for traders tracking relative performance and market positioning across the small-cap technology space, as well as for longer-term investors weighing a recovery narrative against a high-risk transformation.

DDD Overview and Recent Performance

3D Systems Corporation (DDD) is a Rock Hill, South Carolina-based provider of 3D printing hardware, materials, software, and on-demand parts for healthcare and industrial markets. Its operations fall into Healthcare Solutions and Industrial Solutions segments. In recent quarters, the company has shown signs of emerging from a multi-year industry downturn. First-quarter 2026 revenue rose to $95.5 million, with Healthcare Solutions growing roughly 21%, and second-quarter revenue held near $94.6 million as MedTech, Dental, Aerospace & Defense, and Data Center Infrastructure each posted meaningful gains. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Profitability has also trended toward breakeven. Adjusted EBITDA turned slightly positive in the first quarter and improved materially year over year in the second, aided by cost reductions and a tariff refund. The company raised approximately $53 million through a share issuance, lifted its cash position, and announced a CEO transition plan. Despite strong year-to-date price performance, the stock pulled back in recent weeks, and short interest remains elevated at roughly 27% of the float, reflecting continued disagreement among investors about the durability of the turnaround.

VJET Overview and Recent Performance

Flyte Aviation, Inc. (VJET) is the new corporate identity of the former Catheter Precision, a medical device company focused on cardiac arrhythmia treatment. In early 2026, the company acquired full ownership of Flyte, a regional air mobility operator using Cirrus Vision Jets through its FAA-certified Part 135 subsidiary, Ponderosa Air. The company now operates two segments, cardiac electrophysiology and private aviation charter, while exploring strategic options for the legacy medical business.

Effective in early October 2026, the company rebranded to Flyte Aviation, adopted the VJET ticker, and completed a 1-for-10 reverse stock split. The business remains small and unprofitable. Full-year 2025 revenue was approximately $819,000, with a net loss of roughly $17 million, and trailing twelve-month revenue sits near $1.9 million against a substantial net loss. The company has relied on convertible preferred stock and institutional financing to fund operations, and its balance sheet carries meaningful debt relative to its size. These factors make VJET a speculative, early-stage story with limited historical trading data under its new ticker.

Head-to-Head Comparison

The most obvious contrast between these two stocks is scale and maturity. 3D Systems generates roughly $95 million in quarterly revenue and holds over $120 million in cash, while Flyte Aviation reports annual revenue under $2 million and depends on external financing. Their growth drivers also differ: DDD is focused on refreshing its printer portfolio and expanding high-value healthcare and aerospace applications, whereas VJET is building a new aviation business while still weighing the future of its legacy medical segment.

Risk profiles are equally divergent. 3D Systems faces margin pressure from a hardware-heavy revenue mix, elevated short interest, and the challenge of sustaining profitability, but it has a diversified customer base and a strengthened balance sheet. Flyte Aviation confronts liquidity constraints, a reverse stock split, recurring operating losses, and the execution risk inherent in a newly assembled aviation operation. Market sentiment reflects these differences, with DDD holding a broad analyst "Buy" consensus and VJET carrying limited coverage and a sharply negative trailing performance profile. For sector exposure, DDD offers a direct play on additive manufacturing, while VJET blends a niche medical device franchise with early-stage regional air mobility.

Tickeron AI Verdict

Based on observable factors such as trend consistency, financial stability, and relative positioning, Tickeron's AI would likely favor DDD over VJET in the current environment. 3D Systems exhibits a more established revenue base, improving profitability metrics, clearer end-market catalysts, and a stronger balance sheet, all of which tend to support more stable trend signals. Flyte Aviation's recent ticker change, reverse split, ongoing losses, and early-stage business transformation introduce higher volatility and less reliable price history. While either name could generate short-term momentum under the right conditions, the balance of observable evidence currently positions DDD as the comparatively more stable and better-supported candidate from an AI-driven screening perspective.

Exploring Tickeron AI Trading Bots

When I want a data-driven view on names like these, I often look at Tickeron’s AI Trading Bots. The platform hosts hundreds of bots, each built around its own strategy, timeframe, and performance statistics. Reviewing the curated selection helps identify approaches that align with current market conditions without having to test every option manually.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: DDD, VJET

Contributor

John Y White's AvatarJohn Y White|Beginner

Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active&section=trades&via=john


DDD in upward trend: price rose above 50-day moving average on September 17, 2026

DDD moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend. In 25 of 32 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 17, 2026. You may want to consider a long position or call options on DDD as a result. In 59 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

The Moving Average Convergence Divergence (MACD) for DDD just turned positive on September 18, 2026. Looking at past instances where DDD's MACD turned positive, the stock continued to rise in 36 of 49 cases over the following month. The odds of a continued upward trend are 73%.

Following a +15.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where DDD advanced for three days, in 174 of 223 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 58 cases where DDD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DDD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

DDD broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for DDD entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. DDD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.138) is normal, around the industry mean (7.187). P/E Ratio (6.432) is within average values for comparable stocks, (51.474). Projected Growth (PEG Ratio) (15.430) is also within normal values, averaging (23.994). Dividend Yield (0.000) settles around the average of (0.004) among similar stocks. P/S Ratio (1.271) is also within normal values, averaging (51.774).

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DDD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.

Notable companies

The most notable companies in this group are Dell Technologies (NYSE:DELL), Arista Networks Inc (NYSE:ANET), Seagate Technology Holdings PLC (NASDAQ:STX), Western Digital Corp (NASDAQ:WDC), HP (NYSE:HPQ), 3D Systems Corp (NYSE:DDD).

Industry description

Computer Processing Hardware industry produces central processing unit, monitor, keyboard, computer data storage devices, and graphics card. Business activity and economic growth are potential drivers of this industry – if more businesses are growing or flourishing, so would their investments in computer equipment. Dell Technologies, Inc, Hewlett Packard Enterprise Co., NCR Corporation are key producers of computer processing hardware.

Market Cap

The average market capitalization across the Computer Processing Hardware Industry is 31.54B. The market cap for tickers in the group ranges from -0.18 to 345.52B. DELL holds the highest valuation in this group at 345.52B. The lowest valued company is HAUP at -0.18.

High and low price notable news

The average weekly price growth across all stocks in the Computer Processing Hardware Industry was 3%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 39%. QTEX experienced the highest price growth at 124%, while XTND experienced the biggest fall at -19%.

Volume

The average weekly volume growth across all stocks in the Computer Processing Hardware Industry was 87%. For the same stocks of the Industry, the average monthly volume growth was 68% and the average quarterly volume growth was -1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 44
P/E Growth Rating: 65
Price Growth Rating: 53
SMR Rating: 80
Profit Risk Rating: 86
Seasonality Score: 21 (-100 ... +100)
View a ticker or compare two or three
DDD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of 3-D printing, prototyping and manufacturing computer-aided design systems and services

Industry ComputerProcessingHardware

Industry
Electronic Equipment Or Instruments
Address
333 Three D Systems Circle
Phone
+1 803 326-3900
Employees
1418
Web
https://www.3dsystems.com
Interact to see
Advertisement
I've been following ANTX, a biopharmaceutical company based in Menlo Park, California, that develops novel small molecule therapeutics from its proprietary boron chemistry platform. The focus is on underserved areas like infectious diseases, with the lead candidate epetraborole advancing in Phase 3 trials for non-tuberculous mycobacterial (NTM) lung disease and acute melioidosis. The pipeline also includes AN2-502998 for chronic Chagas disease in preclinical stages, along with programs in oncology.
Tilly's, Inc. (TLYS) operates as a specialty retailer specializing in casual apparel, footwear, accessories, and hardgoods aimed at young men, women, boys, and girls. The company focuses on branded fashion inspired by action sports, surf, and skate culture, offering products like tops, bottoms, swimwear, backpacks, hats, and sunglasses from well-known brands such as Vans and Hurley. With approximately 223 stores in malls and lifestyle centers, complemented by e-commerce through www.tillys.com, Tilly's effectively combines physical and digital sales channels.
Aemetis, Inc. (AMTX) is a renewable natural gas and renewable fuels company focused on developing and commercializing low- and negative-carbon intensity products that replace petroleum-based fuels. The company operates through segments including California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. Its core business model centers on converting agricultural waste—such as dairy manure into biogas and corn/wood waste into ethanol—into high-value biofuels like renewable natural gas (RNG), ethanol, biodiesel, and sustainable aviation fuel precursors.
Silvaco Group, Inc. (SVCO) provides technology computer-aided design (TCAD) software, electronic design automation (EDA) software, and semiconductor intellectual property (SIP) solutions. The company helps semiconductor and photonics firms design, simulate, and optimize processes from atomic-level modeling to complex system-on-chip (SoC) development. Its business centers on licensing software tools and IP blocks, along with engineering services, targeting high-growth areas like AI, power devices, automotive, foundries, and 5G/6G mobile.
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
RH shares are down approximately 17% in premarket trading on April 1, 2026, after closing the previous session at $139.82, with the stock indicated near $115.76 — a decline of roughly $24 per share. The primary catalyst is a significant Q4 fiscal year 2025 earnings miss, with adjusted EPS of $1.53 coming in well below the Wall Street consensus of $2.22 — a 31% negative surprise.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ORIC Pharmaceuticals shares are down approximately 21% in premarket trading on April 1, 2026, from a prior session close of approximately $12.19, placing the premarket price near $9.63. The primary catalyst is the after-market release of Phase 1b dose optimization data for rinzimetostat (ORIC-944) on March 31, alongside the selection of 400 mg once daily as the recommended Phase 3 dose for the Himalayas-1 registrational trial.
Shares of Target Hospitality Corp. (Nasdaq: TH) surged approximately 38% during Wednesday's trading session, climbing from a prior close of $9.28 to approximately $12.81. The primary catalyst is the company's announcement of a landmark multi-year lease and services agreement worth over $550 million with a top-five global hyperscaler to build and operate a data center workforce community in North Texas.
Shares of Turning Point Brands (TPB) are falling sharply intraday on April 1, 2026, shedding approximately 15% from their prior session close of roughly $87.41, placing the stock near $74.30. The primary catalyst is broad investor risk-off selling tied to mounting trade-policy uncertainty ahead of President Trump's sweeping tariff announcements scheduled for April 2 — a day the administration has branded "Liberation Day".
Shares of Philip Morris International fell approximately 8% during intraday trading on April 1, 2026, dropping from a prior close of $165.34 to around $152.11. A sharp, broad-based market selloff — amplified by renewed trade policy tensions — is acting as the primary macro catalyst behind the decline.
WDC shares surged approximately +10% in Wednesday's session, advancing to approximately $296–$297 from a prior close near $269.82 on March 31, 2026. The primary catalyst is a major analyst upgrade: Bernstein raised its rating on Western Digital from Market Perform to Outperform and dramatically doubled its price target to $340 from $170.
I've been following CG Oncology, Inc. (CGON), a late-stage clinical biopharmaceutical company dedicated to developing and commercializing cretostimogene grenadenorepvec. This investigational oncolytic immunotherapy aims to serve as a bladder-sparing therapeutic for patients with non-muscle invasive bladder cancer (NMIBC). The company's focus remains on pushing this intravesical therapy through Phase 3 trials to address high unmet needs in BCG-unresponsive and intermediate-risk NMIBC, where treatments like BCG frequently fall short. In the broader biotech landscape, CG Oncology stands out with cretostimogene's encouraging durability and tolerability, which could position it as a foundational therapy. From what I see, these solid fundamentals—bolstered by strong clinical data and regulatory steps—have directly supported the recent stock price gains amid positive trial developments.
From what I see, Home Depot (HD) remains the world's largest home improvement retailer, operating over 2,300 stores across North America with a broad selection of products for construction, renovation, and maintenance. The company blends big-box retail with an expanding e-commerce platform and tailored services for professional contractors, drawing revenue from both do-it-yourself (DIY) consumers and do-it-for-me (DIFM) pros. In a competitive landscape against players like Lowe's, HD maintains dominance through its scale, efficient supply chain, and strong loyalty programs. Much of its performance ties directly to the housing market—home sales, remodeling, and repairs—which explains the recent pressure on the stock from subdued activity and high mortgage rates limiting turnover and major projects.
3D Systems (DDD) vs. Flyte Aviation (VJET): Contrasting Paths in 3D Technology